Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-18
2010-11-23
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S093730
Reexamination Certificate
active
07837997
ABSTRACT:
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
REFERENCES:
patent: 6443976 (2002-09-01), Flower et al.
patent: 6488927 (2002-12-01), Muzykantov
patent: 7041287 (2006-05-01), Muzykantov
patent: 7172760 (2007-02-01), Muzykantov
patent: 485749 (1992-05-01), None
patent: 60200169 (1985-10-01), None
Bode et al. J. Biol. Chem., vol. 264, No. 2, Jan. 1989, pp. 944-948.
Kajihara et al, Physicochemical characterization of PEG-PPG conjugated human urokinase, Biochimica et Biophysica Acta, Mar. 1994, vol. 1199, No. 2, pp. 202-208.
Muzykantov et al, Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin, Analytical Biochemistry, Oct. 1996, vol. 241, No. 1, pp. 109-119.
Bdeir et al, Urokinase mediates fibrinolysis in the pulmonary microvasculature, Blood, Sep. 2000, vol. 96, No. 5, pp. 1820-1826.
Collen D, Towards improved thrombolytic therapy, Lancet, Jul. 1993, vol. 342, No. 8862, pp. 34-36.
Collen et al, Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase, European J Biochemistry, Aug. 1993, vol. 216, No. 1, pp. 307-314.
Fears et al, Obstacles to the development of novel thrombolytic agents for acute myocardial infarction therapy: Is the good the enemy of the best?, Fibrinolysis, 1994, vol. 8, pp. 203-213.
Heeremans et al, Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA, J. Thrombosis and Haemostasis, Mar. 1995 , vol. 73, No. 3, pp. 488-494.
Holvoet et al, Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates, Circulation, Mar. 1993, vol. 87, No. 3, pp. 1007-1016.
Kolofonos et al., Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication, J Nuclear Medicine, Nov. 1990, vol. 31, No. 11, pp. 1791-1796.
Kinoshita et al, Survival of sucrose-loaded erythrocytes in the circulation, Nature, Mar. 1978, vol. 272, pp. 258-260.
Krishnamurti et al, PAI-1-resistant t-PA: low doses prevent fibrin deposition in rabbits with increased PAI-1 activity, Blood, Jan. 1996, vol. 87, No. 1, pp. 14-19.
Lijnen et al, Remaining perspectives of mutant and chimeric plasminogen activators, Annals of the New York Academy Science, Dec. 1992, vol. 667, pp. 357-364.
Murciano et al, Platelets inhibit the lysis of pulmonary microemboli, American J Physiology Lung Cellular and Molecular Physiology, Mar. 2002, vol. 282, No. 3, pp. L529-L539.
Muzykantov et al, Targeting of enzyme immobilized on erythrocyte membrane to collagen-coated surface, FEBS Letters, Mar. 1985, vol. 182, No. 1, pp. 62-66.
Muzykantov et al, Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide, American J Pathology, Aug. 1987, vol. 128, No. 2, pp. 276-285.
Muzykantov et al, Avidin-induced lysis of biotinylated erythrocytes by homologous complement via the alternative pathway depends on avidin's ability of multipoint binding with biotinylated membrane, Biochim Biophys Acta., Jun. 1992, vol. 1107, No. 1, pp. 119-125.
Muzykantov et al, Avidin acylation prevents the complement-dependent lysis of avidin-carrying erythrocytes, Biochemical J., Jan. 1991, vol. 273, part 2, pp. 393-397.
Muzykantov et al, Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes, International J Artificial Organs, Oct. 1992, vol. 15, No. 10, pp. 622-627.
Muzykantov et al, Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot, Biochim Biophys Acta. Nov. 1986, vol. 884, No. 2, pp. 355-362.
Muzykantov et al, Tannin-mediated attachment of avidin provides complement-resistant immunoerythrocytes that can be lysed in the presence of activator of complement, Analytical Biochemistry, Feb. 1993, vol. 208, No. 2, pp. 338-342.
Muzykantov et al, Immunotargeting of antioxidant enzyme to the pulmonary endothelium, Proc Natl Acad Sci U S A., May 1996, vol. 93, No. 11, pp. 5213-5218.
Narita et al, Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo, J Clinical Investigation, Aug. 1995, vol. 96, No. 2, pp. 1164-1168.
Pardridge et al, Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo, Proc Natl Acad Sci U S A., Jun. 1995, vol. 92, No. 12, pp. 5592-5596.
Plow et al, The cell biology of the plasminogen system, FASEB J., Jul. 1995, vol. 9, No. 10, pp. 939-945.
Poznansky et al, Biological approaches to the controlled delivery of drugs: a critical review, Pharmacology Review, Dec. 1984, vol. 36, No. 4, pp. 277-336.
Reilly et al, Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat, Arteriosclerosis, Thrombosis and Vascular Biology, Sep.-Oct. 1991, vol. 11, No. 5, pp. 1276-1286.
Sakharov et al, Superficial accumulation of plasminogen during plasma clot lysis, Circulation, Oct. 1995, vol. 92, No. 7, pp. 1883-1890.
Samohkin et al, Red blood cell targeting to collagen-coated surfaces, FEBS Letters, Apr. 1983, vol. 154, No. 2, pp. 257-261.
Schnaper et al, Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways, J Cellular Physiology, Oct. 1995, vol. 165, No. 1, pp. 107-118.
Wilchek et al, The avidin-biotin complex in bioanalytical applications, Analytical Biochemistry, May 1988, vol. 171, No. 1, pp. 1-32.
Muzykantov et al, Attachment of biotinylated antibody to red blood cells: antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement, Analytical Biochemistry, Nov. 1994, vol. 223, No. 1, pp. 142-148.
Heeremans, et al, The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage, J Drug Targeting, Dec. 1995, vol. 3, No. 4, pp. 301-310.
Lutz et al, Density separation of human red blood cells on self forming Percoll gradients: correlation with cell age, Biochim Biophys Acta., Mar. 1992, vol. 1116, No. 1, pp. 1-10 (abstract only).
Birmingham et al, Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates, J Laboratory Clinical Medicine, Aug. 1990, vol. 116, No. 2, pp. 242-252 (abstract only).
Collen et al, Fibrin-selective thrombolytic therapy for acute myocardial infarction, Circulation, Mar. 1996, vol. 93, No. 5, pp. 857-865.
Higazi et al, Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1, Blood, May 1996, vol. 87, No. 9, pp. 3545-3549.
Higazi et al, Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor, J Biological Chemistry, Jul. 1995, vol. 270, No. 29, pp. 17375-17380.
Muzykantov et al, Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement, Blood, Nov. 1991, vol. 78, No. 10, pp. 2611-2618.
Muzykantov et al, The functional effects of biotinylation of anti-angiotensin-converting enzyme monoclonal antibody in terms of targeting in vivo, Analytical Biochemistry, Apr. 1995, vol. 226, No. 2, pp. 279-287.
Muzykantov et al, Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature, J Pharmacology and Experimental Therapeutics, Nov. 1996, vol. 279, No. 2, pp. 1026-1034.
Runge et al, Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons, Circulation, Sep. 1996, vol. 94, No. 6, pp. 1412-1422.
Suzuki et al, Biotinylated erythrocytes: in vivo survival and in vitro recovery, Blood, Sep. 1987, vol. 70, No. 3, pp. 791-795.
Zaltman et al, Enhanced complement susceptibility of avidin-biotin-treated
Cines Douglas
Higazi Abd Al-Roof
Murciano Juan Carlos
Muzykantov Vladimir R.
Taylor Ronald P.
Borin Michael
Howson & Howson LLP
Trustees of the University of Pennsylvania
University of Virginia Patent Foundation
LandOfFree
Compositions and methods for prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239961